Library

feed icon rss

Your email was sent successfully. Check your inbox.

An error occurred while sending the email. Please try again.

Proceed reservation?

Export
Filter
  • Manische Psychosen  (2)
  • clinical trials  (2)
  • 1
    ISSN: 1432-2072
    Keywords: Schizophrenia ; negative symptoms ; clinical trials ; psychiatric status rating scales ; neuroleptics
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Notes: Abstract There is little agreement about the methodology of clinical trials of antipsychotic drugs in patients with negative symptoms. A literature review revealed wide variation in experimental design, rating scales and study duration. This reflects differing views as to the definition and response to treatment of negative symptoms. Some degree of standardization would improve comparability of studies and aid the development of new compounds. Patients included in such studies should have displayed negative symptoms for at least 6 months. Depressive symptoms, positive schizophrenic symptoms and extrapyramidal signs may all influence or be confused with negative symptoms and may respond to treatment; they should be at a low level at baseline and should be measured during the study period. Studies should last at least 8 weeks. Several scales are available for measuring negative symptoms and are reviewed; a global impression score should be used additionally.
    Type of Medium: Electronic Resource
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 2
    Electronic Resource
    Electronic Resource
    Springer
    European archives of psychiatry and clinical neuroscience 229 (1980), S. 1-16 
    ISSN: 1433-8491
    Keywords: Manic psychoses ; Valproate ; GABA ; Lithium ; Manische Psychosen ; Valproat ; GABA ; Lithium
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Description / Table of Contents: Zusammenfassung Unter Verwendung eines doppel-blinden ABA-Designs mit Placebo-Kontrolle wurde bei 5 Patienten mit akuter Manie eine mögliche antimanische Wirkung des GABA-ergen Anticonvulsivums Valproat untersucht. Bei 4 Patienten wurde eine deutliche Besserung beobachtet, während ein Patient auf Valproat nicht reagierte. Bei 7 weiteren Patienten mit häufig wiederkehrenden Phasen einer manischen oder maniformen schizoaffektiven Psychose, die auf die Lithium-Prophylaxe nicht ansprachen, wurde eine Dauerbehandlung mit Valproat in Kombination mit kleinen Lithium-Dosen durchgeführt. (In einem Fall wurde nur Valproat, ohne Lithium, gegeben.) Im Verlauf einer Beobachtungsphase von 1 1/2–3 Jahren wurde bei keinem dieser Patienten ein Rückfall beobachtet. Es wird die Hypothese vorgeschlagen, daß grundsätzlich GABA-erge Anticonvulsiva antimanische Eigenschaften aufweisen und daß auch der spezifische antimanische Effekt von Lithium auf einer GABA-ergen Wirkungskomponente beruht. Eine mögliche pathophysiologische Bedeutung zentraler GABA-Systeme bei affektiven und organischen Psychosen (z.B. Porphyrie, Delirium tremens) wird auf der Basis pharmakopsychiatrischer Überlegungen diskutiert.
    Notes: Summary A possible antimanic property of the GABA-ergic anticonvulsant valproate was examined by use of a double-blind placebo-controlled ABA design in 5 acutely ill manic patients. In 4 cases a marked improvement was observed after valproate medication whereas one patient showed no response. Seven further patients with frequently recurrent episodes of a manic or maniform schizoaffective psychosis, irresponsive to lithium prophylaxis, were chronically treated with valproate in combination with low doses of lithium (one case only with valproate). Over an observation period of 1 1/2–3 years none of the patients exhibited a relapse. It is proposed that, in general, GABA-ergic anticonvulsants possess antimanic properties and that the specific antimanic effect of lithium is due to a GABA-ergic mode of action. The possible role of GABA-systems in affective disorders and in organic types of psychoses (e.g., porphyria-psychosis, delirium tremens) is discussed on the basis of pharmacopsychiatric considerations.
    Type of Medium: Electronic Resource
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 3
    Electronic Resource
    Electronic Resource
    Springer
    European archives of psychiatry and clinical neuroscience 227 (1979), S. 301-317 
    ISSN: 1433-8491
    Keywords: Manic psychoses ; Beta blockers ; Manische Psychosen ; Beta-Blocker
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Description / Table of Contents: Zusammenfassung Im Rahmen einer doppelblind durchgeführten, placebokontrollierten Studie wurden sechs manische Patienten mit hohen Dosen doder d- und dl-Propranolol behandelt. Dabei wurden folgende Variablen gemessen: Propranolol-Dosis, Propranolol-Serumkonzentration, Pulsfrequenz, Blutdruck und Psychopathologie. In allen Fällen konnte eine klinische Besserung festgestellt werden, aber hohe Dosen waren erforderlich, um einen befriedigenden therapeutischen Effekt zu erreichen. Die antimanische Wirksamkeit von d-Propranolol erschien, verglichen mit der von dl-Propranolol, um etwa 50% geringer. Aus diesem Ergebnis kann geschlossen werden, daß wenigstens ein Teil der antimanischen Wirksamkeit von Beta-Blockern unabhängig ist von den beta-blockierenden Eigenschaften dieser Substanzen.
    Notes: Summary Six manic patients were treated with high doses of d-propranolol or d- and dl-propranolol in a double-blind, placebo controlled study. The following variables were measured: propranolol dosage, propranolol serum concentration, pulse frequency, blood pressure, and psychotic behavior. In all cases an improvement was noticed. High dosages were necessary to obtain sufficient effect. The antimanic property of d-propranolol was approximately 50% smaller than the antimanic property of dl-propranolol. We conclude that at least some part of the antimanic action of beta-blockers is independent from the beta-blocking property.
    Type of Medium: Electronic Resource
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 4
    Electronic Resource
    Electronic Resource
    Springer
    Journal of neural transmission 103 (1996), S. 217-245 
    ISSN: 1435-1463
    Keywords: Brofaromine ; reversible and selective inhibitors of monoamine oxidase (type A) ; pharmacology ; clinical trials
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Notes: Summary The antidepressant activity of monoamine oxidase inhibitors has been well established for 30 years. Nevertheless, this group of compounds was handled with great care, mainly because of the interaction potential with tyramine-containing foodstuff. With the discovery of reversible and selective inhibitors of monoamine oxidase type A a renaissance of these compounds has begun. In this paper one of these new substances — brofaromine — will be described in detail. Biochemical and pharmacological aspects will be reviewed, showing that brofaromine is a selective and reversible inhibitor of monoamine oxidase type A with additional serotonin reuptake inhibiting properties. Both mechanisms of action may synergize in the antidepressant effect of the compound. The main results of clinical trials in depression and other indication areas will also be covered. Special attention will be put on the side effect profile.
    Type of Medium: Electronic Resource
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
Close ⊗
This website uses cookies and the analysis tool Matomo. More information can be found here...